Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Ascelia Pharma – Presentation of Full year and Q4 report

By HC Andersen Capital
Ascelia Pharma

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit questions for the event.

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on February 7th. at 1:30 PM.

In 2024, the company received positive headline data from the Orviglance SPARKLE Phase 3 study, along with the full data package from this study, which meets both the primary and secondary endpoints. At the same time, the company completed a capital increase to strengthen its financial position ahead of finalizing a partnership agreement. Key focus areas for 2025 include securing a partnership agreement and submitting an NDA application to FDA for the approval of Orviglance.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmo, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 10.30 23-01-2025

Recent videos

Carasent, Audiocast, Q1'26
14.04.2026 klo 09.00 Carasent
Revenio’s press conference on the Visionix acquisition
13.04.2026 klo 14.00 Revenio Group
Duell, Webcast, Q2'26
09.04.2026 klo 10.30 Duell
Thule Group, Audiocast, Pre-silent 26
30.03.2026 klo 17.00 Thule Group
Puuilo Q4’25: Still the star in the sector
30.03.2026 klo 14.35 Puuilo
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.